Teores de aminoácidos e fenóis em plântulas de algodoeiro (Gossypium hirsutum L. cv. 'IAC-17') sob ação de reguladores vegetais

This research deals with the effects of exogenous growth regulators on dry weight, contents of aminoacids and phenolic compounds in leaves of cotton plants. To study the influence of the chemicals, cotton seeds were immersed during 22 hours in water solutions of (2-chloroethyl) trimethylammonium chloride (CCC) at concentration of 2000 ppm, succinic acid-2,2-dimethylhydrazide 4000 ppm,gibberellic acid 100 ppm, indolylacetic acid (IAA) 100 ppm, and water as check treatment. CCC 2000 ppm increased the dry weight in the leaves of cotton plants. This growth retardant increased the content of free aminoacids in cotton leaves. IAA 100 ppm reduced the concentration of aminoacids in the treated plants. The contents of phenolic compounds in leaves of cotton was increased by CCC, in relation to check treatment.Verificaram-se os efeitos da aplicação de reguladores de crescimento na porcentagem de materia seca, aminoácidos livres totais e compostos fenólicos nas folhas de algodoeiro 'lAC-l7'. Para se estudar a ação dos fitoreguladores, sementes de algodoeiro foram imersas durante 22 horas em soluções aquosas de cloreto (2-cloroetil) trimetilamônio (CCC) na concentração de 2000 ppm, ácido succínico-2,2-dimetilhidrazida 4000 ppm, ácido giberélico 100 ppm, ácido indolilacético (IAA) 100 ppm e água como controle. Plântulas com 33 dias de idade foram coletadas, sendo em seguida realizada a amostragem de folhas em laboratório, para efetuar-se a extração dos compostos. Observou-se que CCC 2000 ppm promoveu aumento no peso seco das folhas de algodoeiro. Esse retardador de crescimento aumentou o conteúdo de aminoácidos livres totais nas folhas estudadas. IAA 100 ppm reduziu a concentração de aminoácidos, nas plantas tratadas. O teor de fenóis totais nas folhas de Gossypium hirsutum foi aumentado por efeito do CCC com relação ao controle

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362